{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:26:53Z","timestamp":1748824013421,"version":"3.40.5"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejca.2017.02.025","type":"journal-article","created":{"date-parts":[[2017,3,26]],"date-time":"2017-03-26T20:01:40Z","timestamp":1490558500000},"page":"24-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6139-9524","authenticated-orcid":false,"given":"M.A.","family":"Frouws","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Rademaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Bastiaannet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.P.P.","family":"van Herk-Sukel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.E.","family":"Lemmens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.J.H.","family":"Van de Velde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0246-1631","authenticated-orcid":false,"given":"J.E.A.","family":"Portielje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.J.","family":"Liefers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2017.02.025_bib1","doi-asserted-by":"publisher","first-page":"e0152402","DOI":"10.1371\/journal.pone.0152402","article-title":"Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies","volume":"11","author":"Elwood","year":"2016","journal-title":"PLoS One"},{"issue":"9754","key":"10.1016\/j.ejca.2017.02.025_bib2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2017.02.025_bib3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11888-016-0306-9","article-title":"Aspirin and colorectal cancer prevention and treatment: is it for everyone?","volume":"12","author":"Coyle","year":"2016","journal-title":"Curr Colorectal Cancer Rep"},{"issue":"9","key":"10.1016\/j.ejca.2017.02.025_bib4","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/ijc.29847","article-title":"Platelets in cancer metastasis: to help the \u201cvillain\u201d to do evil","volume":"138","author":"Li","year":"2016","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.025_bib5","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1055\/s-0037-1615093","article-title":"Platelet count and survival in patients with colorectal cancer\u2013a preliminary study","volume":"79","author":"Monreal","year":"1998","journal-title":"Thromb Haemost"},{"issue":"9826","key":"10.1016\/j.ejca.2017.02.025_bib6","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","article-title":"Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.025_bib7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1538-7836.2010.04131.x","article-title":"The platelet contribution to cancer progression","volume":"9","author":"Bambace","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.025_bib8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ejca.2009.09.010","article-title":"New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System","volume":"46","author":"van Herk-Sukel","year":"2010","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2017.02.025_bib9","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.2337\/dc12-0788","article-title":"Metformin and the risk of cancer: time-related biases in observational studies","volume":"35","author":"Suissa","year":"2012","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ejca.2017.02.025_bib10","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/aje\/kwi307","article-title":"Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods","volume":"162","author":"Zhou","year":"2005","journal-title":"Am J Epidemiol"},{"year":"2016","series-title":"ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Levine","key":"10.1016\/j.ejca.2017.02.025_bib11"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.025_bib12","first-page":"14","article-title":"NHG-standard Cardiovasculair risicomanagement (Eerste herziening) Huisarts Wet","volume":"55","year":"2012"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.025_bib13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10654-010-9451-7","article-title":"Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies","volume":"25","author":"Stricker","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"9","key":"10.1016\/j.ejca.2017.02.025_bib14","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9","article-title":"TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer","volume":"80","author":"Sobin","year":"1997","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.025_bib15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-11-1872","article-title":"Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells","volume":"72","author":"Placke","year":"2012","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.025_bib16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrclinonc.2011.199","article-title":"The role of aspirin in cancer prevention","volume":"9","author":"Thun","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.025_bib17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/1940-6207.CAPR-16-0094","article-title":"Inhibition of the biosynthesis of prostaglandin E2 by low-dose aspirin: implications for adenocarcinoma metastasis","volume":"9","author":"Boutaud","year":"2016","journal-title":"Cancer Prev Res (Phila)"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.025_bib18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamainternmed.2014.511","article-title":"Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer","volume":"174","author":"Reimers","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.025_bib19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"},{"issue":"44","key":"10.1016\/j.ejca.2017.02.025_bib20","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1093\/eurheartj\/eht058","article-title":"Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?","volume":"34","author":"Patrono","year":"2013","journal-title":"Eur Heart J"},{"issue":"Suppl. 3","key":"10.1016\/j.ejca.2017.02.025_bib21","doi-asserted-by":"publisher","first-page":"234S","DOI":"10.1378\/chest.126.3_suppl.234S","article-title":"Platelet-active drugs: the relationships among dose, effectiveness, and side effects : the seventh ACCP conference on antithrombotic and thrombolytic therapy","volume":"126","author":"Patrono","year":"2004","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.025_bib22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI20986","article-title":"Central role of the P2Y12 receptor in platelet activation","volume":"113","author":"Dorsam","year":"2004","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.025_bib23","doi-asserted-by":"publisher","first-page":"s39","DOI":"10.1161\/ATVBAHA.107.160226","article-title":"Translational therapeutics of dipyridamole","volume":"28","author":"Kim","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejca.2017.02.025_bib24","article-title":"Antiplatelet and anticoagulant therapies for prevention of ischemic stroke","author":"Kapil","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.ejca.2017.02.025_bib25","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/1471-2407-8-380","article-title":"Role of cAMP in the promotion of colorectal cancer cell growth by prostaglandin E2","volume":"8","author":"Loffler","year":"2008","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2017.02.025_bib26","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/pds.3807","article-title":"Clopidogrel use and cancer-specific mortality: a population-based cohort study of colorectal, breast and prostate cancer patients","volume":"24","author":"Hicks","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.025_bib27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/jnci\/80.2.90","article-title":"Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188","volume":"80","author":"Zacharski","year":"1988","journal-title":"J Natl Cancer Inst"},{"issue":"9759","key":"10.1016\/j.ejca.2017.02.025_bib28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejca.2017.02.025_bib29","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamainternmed.2016.2648","article-title":"Aspirin for primary prevention of atherosclerotic cardiovascular disease: advances in diagnosis and treatment","volume":"176","author":"Mora","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.025_bib30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.critrevonc.2009.11.004","article-title":"Cancer patients with cardiovascular disease have survival rates comparable to cancer patients within the age-cohort of 10 years older without cardiovascular morbidity","volume":"76","author":"Janssen-Heijnen","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.025_bib31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.critrevonc.2005.04.008","article-title":"Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach","volume":"55","author":"Janssen-Heijnen","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.025_bib32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.15256\/joc.2014.4.41","article-title":"Competing risks of cancer mortality and cardiovascular events in individuals with multimorbidity","volume":"4","author":"Bayliss","year":"2014","journal-title":"J Comorbidity"},{"issue":"25","key":"10.1016\/j.ejca.2017.02.025_bib33","first-page":"A5836","article-title":"Secondary prevention with clopidogrel after TIA or stroke","volume":"157","author":"Zuurbier","year":"2013","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"7","key":"10.1016\/j.ejca.2017.02.025_bib34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(02)00789-1","article-title":"Platelets and cancer","volume":"3","author":"Nash","year":"2002","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2017.02.025_bib35","doi-asserted-by":"crossref","first-page":"32462","DOI":"10.18632\/oncotarget.8655","article-title":"Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells","volume":"7","author":"Guillem-Llobat","year":"2016","journal-title":"Oncotarget"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T01:55:04Z","timestamp":1568944504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917307918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":35,"alternative-id":["S0959804917307918"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.025","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}